Salazopyrin-induced fulminant hepatitis in two children treated for Crohn's disease.

被引:9
作者
Besnard, M
Debray, D
Durand, P
Fabre, M
Chardot, C
Cézard, JP
机构
[1] Hop Robert Debre, Serv Gastroenterol & Nutr Pediat, F-75019 Paris, France
[2] Hop Bicetre, Serv Hepatol Pediat, F-94275 Le Kremlin Bicetre, France
[3] Hop Bicetre, Serv Reanimat Pediat, F-94275 Le Kremlin Bicetre, France
[4] Hop Bicetre, Serv Anatomopathol, F-94275 Le Kremlin Bicetre, France
[5] Hop Bicetre, Serv Chirurg Pediat, F-94275 Le Kremlin Bicetre, France
来源
ARCHIVES DE PEDIATRIE | 1999年 / 6卷 / 06期
关键词
hepatic encephalopathy; child; Crohn disease; liver transplantation; salicylates sulfasalazine;
D O I
10.1016/S0929-693X(99)80296-6
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The main adverse effects of salazopyrin are usually dose-dependant and mild. Exceptionally, idiosyncratic reactions occur which may be life-threatening. Case reports. - Two 10-year old children were treated for Crohn's disease with salazopyrin. At day 21 and day 10 respectively, pharyngitis, rash, and fever were noted. During the following days, high-grade fever persisted, while jaundice, severe cytolysis and acute liver failure also occurred. Drug hepatoxicity was suspected and salazopyrin was withdrawn on day 29 and day 24 respectively. Development of hepatic encephalopathy led to urgent liver transplantation in both cases. Conclusion. - Salazopyrin is a possible cause of fulminant immunoallergic hepatis. Prompt therapeutic interruption is urgent, but it may not alter the outcome and or preclude the need for liver transplantation. We suggest that salazopyrin therapy be avoided in pediatric inflammatory bowel disease whenever possible, and that the use of pure amino- salicylates be preferred. (C) 1999 Elsevier, Paris.
引用
收藏
页码:643 / 646
页数:4
相关论文
共 13 条
[1]   A CONTROLLED DOUBLE-BLIND MULTICENTER STUDY OF THE EFFECTIVENESS OF 5-AMINOSALICYLIC ACID IN PATIENTS WITH CROHNS-DISEASE IN REMISSION [J].
ARBER, N ;
ODES, HS ;
FIREMAN, Z ;
LAVIE, A ;
BROIDE, E ;
BUJANOVER, Y ;
BECKER, S ;
POMERANTZ, I ;
MOSHKOWITZ, M ;
PATZ, J ;
GILAT, T .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 (03) :203-206
[2]   SULFASALAZINE-INDUCED HEPATOTOXICITY IN CHILDREN WITH INFLAMMATORY BOWEL-DISEASE [J].
BOYER, DL ;
LI, BUK ;
FYDA, JN ;
FRIEDMAN, RA .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1989, 8 (04) :528-532
[3]   HEPATOTOXICITY AFTER TREATMENT WITH SULFASALAZINE [J].
HAINES, JD .
POSTGRADUATE MEDICINE, 1986, 79 (06) :193-&
[4]   HYPERSENSITIVITY WITH HEPATOTOXICITY TO MESALAZINE AFTER HYPERSENSITIVITY TO SULFASALAZINE [J].
HAUTEKEETE, ML ;
BOURGEOIS, N ;
POTVIN, P ;
DUVILLE, L ;
REYNAERT, H ;
DEVIS, G ;
ADLER, M ;
KLOPPEL, G .
GASTROENTEROLOGY, 1992, 103 (06) :1925-1927
[5]  
LARCAN A, 1982, THERAPIE, V37, P315
[6]   SULFASALAZINE-INDUCED FULMINANT HEPATIC-FAILURE [J].
MARINOS, G ;
RILEY, J ;
PAINTER, DM ;
MCCAUGHAN, GW .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1992, 14 (02) :132-135
[7]  
Marteau P, 1997, GASTROEN CLIN BIOL, V21, P377
[8]  
MUNAKATA A, 1995, J GASTROENTEROL, V30, P108
[9]  
NAKAJIMA H, 1995, J GASTROENTEROL, V30, P115
[10]  
RIBE J, 1986, AM J GASTROENTEROL, V81, P205